These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 39091915)

  • 1. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.
    Gorantla SP; Prince G; Osius J; Dinesh DC; Boddu V; Duyster J; von Bubnoff N
    Front Oncol; 2024; 14():1430833. PubMed ID: 39091915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
    Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
    Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2
    Courdy C; Platteeuw L; Ducau C; De Araujo I; Boet E; Sahal A; Saland E; Edmond V; Tavitian S; Bertoli S; Cougoul P; Granat F; Poillet L; Marty C; Plo I; Sarry JE; Manenti S; Mansat-De Mas V; Joffre C
    Blood Cancer J; 2023 Jul; 13(1):106. PubMed ID: 37423955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
    Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
    F1000Res; 2018; 7():82. PubMed ID: 29399328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
    Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
    Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
    Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
    Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms.
    Brkic S; Meyer SC
    Hemasphere; 2021 Jan; 5(1):e516. PubMed ID: 33403355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
    Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
    Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
    Weigert O; Lane AA; Bird L; Kopp N; Chapuy B; van Bodegom D; Toms AV; Marubayashi S; Christie AL; McKeown M; Paranal RM; Bradner JE; Yoda A; Gaul C; Vangrevelinghe E; Romanet V; Murakami M; Tiedt R; Ebel N; Evrot E; De Pover A; Régnier CH; Erdmann D; Hofmann F; Eck MJ; Sallan SE; Levine RL; Kung AL; Baffert F; Radimerski T; Weinstock DM
    J Exp Med; 2012 Feb; 209(2):259-73. PubMed ID: 22271575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin exerts multitarget antileukemia activity in JAK2
    Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
    Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
    Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
    J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
    Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
    Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
    Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
    Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
    Greenfield G; McPherson S; Mills K; McMullin MF
    J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
    Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
    Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.